View Older Stories View More Recent Stories

May 30, 2025 07:30AM TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
May 27, 2025 07:30AM TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
May 5, 2025 07:00AM TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
Apr 30, 2025 07:30AM TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
Apr 10, 2025 07:30AM TG Therapeutics (TGTX) Announces Data Presentations for BRIUMVI
Apr 10, 2025 07:30AM TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
Apr 8, 2025 07:32AM TG Therapeutics (TGTX) Announces Data Presentations for BRIUMVI
Apr 8, 2025 07:30AM TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
Apr 7, 2025 07:32AM TG Therapeutics (TGTX) Announces Two Publications Highlighting BRIUMVI in Medical Journals
Apr 7, 2025 07:30AM TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
Mar 7, 2025 07:30AM TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
Mar 3, 2025 07:00AM TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Feb 27, 2025 07:32AM TG Therapeutics (TGTX) Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Feb 27, 2025 07:30AM TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Feb 26, 2025 07:30AM TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
Feb 18, 2025 07:30AM TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Jan 14, 2025 07:04AM TG Therapeutics (TGTX) Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
Jan 14, 2025 07:00AM TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
Jan 9, 2025 07:30AM TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Nov 29, 2024 08:00AM TG Therapeutics to Participate in the Evercore HealthCONx Conference
Nov 21, 2024 06:00AM TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Nov 4, 2024 07:00AM TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
Nov 1, 2024 08:06AM TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
Sep 18, 2024 07:15AM TG Therapeutics (TGTX): New BRIUMVI Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
Sep 18, 2024 07:15AM New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
Sep 18, 2024 07:02AM TG Therapeutics (TGTX) Reports New BRIUMVI Data Showing 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
Sep 18, 2024 07:00AM New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
Sep 5, 2024 07:30AM TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Aug 6, 2024 07:00AM TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
Aug 5, 2024 07:30AM TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
Jun 11, 2024 08:45AM Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
Jun 7, 2024 07:50AM TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Jun 3, 2024 07:30AM TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 31, 2024 07:30AM TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 28, 2024 07:30AM TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 1, 2024 07:00AM TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Apr 30, 2024 04:55PM TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
Apr 18, 2024 07:30AM TG Therapeutics (TGTX) Announces Additional Data Presentations for BRIUMVI in Multiple Sclerosis
Apr 18, 2024 07:30AM TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Apr 18, 2024 07:05AM TG Therapeutics (TGTX) Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Apr 18, 2024 07:00AM TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Apr 15, 2024 07:31AM TG Therapeutics (TGTX) Announces Presentation of Data for BRIUMVI in Multiple Sclerosis
Apr 15, 2024 07:30AM TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Mar 8, 2024 07:30AM TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Mar 1, 2024 07:30AM TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Feb 28, 2024 07:00AM TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
Feb 27, 2024 07:32AM TG Therapeutics (TGTX) Receives Additional Patents for BRIUMVI
Feb 27, 2024 07:30AM TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
Feb 26, 2024 07:04AM TG Therapeutics (TGTX) Announces European Launch of BRIUMVI
Feb 26, 2024 07:00AM TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
View More Recent Stories View Older Stories